Metrics as of 10/17/2026, 05:24 AM (Berlin time), refresh in progress.
Nurix Therapeutics Stock
Nurix Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Arthur T. Sands
- Employees
- 317
- Market cap
- $2.5 B
- IPO
- 24/07/2020
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in Brisbane, California, USA. Founded in 2009, the company focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Nurix Therapeutics stock: price history
1D
-2.1%
1W
+9.3%
1M
-2.9%
6M
+39.5%
YTD
+28.7%
1Y
+143.5%
2Y
-5.4%
5Y
-15.3%
10Y
–
Next earnings date
Next earnings date
27/01/2027 (in 102 days)
Volatility around earnings
~14% stronger price swings than usual
Nurix Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs and antibody therapies for the treatment of cancers and inflammatory conditions. The business model relies substantially on royalties and strategic collaborations for joint development and commercialization of drug candidates, such as BTK degraders. Current revenue is composed of collaboration and licensing revenues, with key programs in clinical Phase 1 or Phase 2 development.
- Revenue model
- Mixed
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Ask the agents about Nurix Therapeutics
Analyst assessment of Nurix Therapeutics
PRICE TARGET LOW
US$31.00
CONSENSUS
US$35.58
MEDIAN
US$34.50
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
19
BUY
0
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 16/10/2026
Nurix Therapeutics stock metrics
P/E
9.73
P/B
2.81
EV/EBITDA
5.83
RETURN ON EQUITY
56.8%
NET MARGIN
81.7%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
31/08/2026
Free float & liquidity
FREE FLOAT
95.2%
FLOAT SHARES
98,841,769
AVG. DAILY VOLUME (30D)
1,897,676
Insider transactions (SEC)
Hansen Gwenn
Hansen Gwenn
GREGORY JULIA P
GREGORY JULIA P
Ring Christine
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Nurix Therapeutics stock
What does Nurix Therapeutics do?
Nurix Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Arthur T. Sands, the company employs around 317 people.
The IPO was on 24/07/2020; the stock trades on NASDAQ under the ticker NRIX.
What do analysts say about Nurix Therapeutics stock?
19 analysts rate the stock, the consensus is Buy (as of 16/10/2026).
The average price target is US$35.58, ranging from US$31.00 to US$45.00, with a median of US$34.50.
This is an external assessment, not a statement by Market Jury.
When does Nurix Therapeutics report next?
The next earnings date is 27/01/2027.
Around past earnings, price swings were roughly 14% stronger than usual.
Does Nurix Therapeutics pay a dividend?
No, Nurix Therapeutics currently does not pay a dividend.
Which stocks are comparable to Nurix Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nurix Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nurix Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.